-
Liverpool's Slot says 'no issue to resolve' with Salah after outburst
-
'Stop the slaughter': French farmers block roads over cow disease cull
-
Stormers see off La Rochelle, Sale stun Clermont in Champions Cup
-
Maresca hails Palmer as Chelsea return to winning ways against Everton
-
Hungarian protesters demand Orban quits over abuse cases
-
Belarus frees protest leader Kolesnikova, Nobel winner Bialiatski
-
Salah sets up goal on return to Liverpool action
-
Palmer strikes as Chelsea return to winning ways against Everton
-
Pogacar targets Tour de France Paris-Roubaix and Milan-San Remo in 2026
-
Salah back in action for Liverpool after outburst
-
Atletico recover Liga momentum with battling win over Valencia
-
Meillard leads 'perfect' Swiss sweep in Val d'Isere giant slalom
-
Salah on Liverpool bench for Brighton match
-
Meillard leads Swiss sweep in Val d'Isere giant slalom
-
Indonesia flood death toll passes 1,000 as authorities ramp up aid
-
Cambodia shuts Thailand border crossings over deadly fighting
-
First urban cable car unveiled outside Paris
-
Vonn second behind Aicher in World Cup downhill at St Moritz
-
Aicher pips Vonn to downhill win at St Moritz
-
Thailand says 4 soldiers killed in Cambodia conflict, denies Trump truce claim
-
Fans vandalise India stadium after Messi's abrupt exit
-
Women sommeliers are cracking male-dominated wine world open
-
Exhibition of Franco-Chinese print master Zao Wou-Ki opens in Hong Kong
-
Myanmar junta denies killing civilians in hospital strike
-
Why SpaceX IPO plan is generating so much buzz
-
Thailand continues Cambodia strikes despite Trump truce calls
-
US envoy to meet Zelensky, Europe leaders in Berlin this weekend
-
North Korea acknowledges its troops cleared mines for Russia
-
US unseals warrant for tanker seized off Venezuelan coast
-
Cambodia says Thailand still bombing hours after Trump truce call
-
Machado urges pressure so Maduro understands 'he has to go'
-
Leinster stutter before beating Leicester in Champions Cup
-
World stocks mostly slide, consolidating Fed-fuelled gains
-
Crypto firm Tether bids for Juventus, is quickly rebuffed
-
Union sink second-placed Leipzig to climb in Bundesliga
-
US Treasury lifts sanctions on Brazil Supreme Court justice
-
UK king shares 'good news' that cancer treatment will be reduced in 2026
-
Wembanyama expected to return for Spurs in NBA Cup clash with Thunder
-
Five takeaways from Luigi Mangione evidence hearings
-
UK's king shares 'good news' that cancer treatment will be reduced in 2026
-
Steelers' Watt undergoes surgery to repair collapsed lung
-
Iran detains Nobel-prize winner in 'brutal' arrest
-
NBA Cup goes from 'outside the box' idea to smash hit
-
UK health service battles 'super flu' outbreak
-
Can Venezuela survive US targeting its oil tankers?
-
Democrats release new cache of Epstein photos
-
Colombia's ELN guerrillas place communities in lockdown citing Trump 'intervention' threats
-
'Don't use them': Tanning beds triple skin cancer risk, study finds
-
Nancy aims to restore Celtic faith with Scottish League Cup final win
-
Argentina fly-half Albornoz signs for Toulon until 2030
US authorizes first condom for use in anal sex
The US Food and Drug Administration (FDA) on Wednesday authorized the first condom for use during anal intercourse, in what was hailed as a victory for sexual health by experts.
Although people already use condoms for anal sex -- as is recommended by health agencies including the Centers for Disease Control and Prevention (CDC) -- regulators across the world had only previously allowed companies to officially market their products as "safe and effective" for vaginal use.
Sexual health advocates considered this an unmet public health need since unprotected anal intercourse carries the greatest risk of HIV transmission via sexual exposure, with one study finding that 69 percent of men who have sex with men would use condoms more frequently if they were FDA-indicated.
Wednesday's authorization of Global Protection Corp's One Male Condom follows a clinical trial involving more than 500 people, carried out by Emory University.
"The FDA's authorization of a condom that is specifically indicated, evaluated and labeled for anal intercourse may improve the likelihood of condom use during anal intercourse," said agency scientist Courtney Lias in a statement.
The condom is also indicated to prevent sexually transmitted infections -- and as a contraceptive -- during vaginal sex.
"We want people to have lots of sex -- but we also want them to be empowered and informed," said Davin Wedel, president of Global Protection Corp, which makes the condom brand that is available in 54 sizes, and incorporates a paper template to help each user find the right size.
The clinical trial involved 252 men who have sex with men and 252 men who have sex with women, aged between 18 and 54.
The FDA had said it would accept a five percent failure rate, which previous trials had failed to accomplish. The limit was easily surpassed in the new study, with the failure rate 0.68 percent for anal and 1.89 percent for vaginal intercourse.
The researchers behind the study, which was published in The Lancet's eClinicalMedicine, said one of the reasons the trial succeeded where others failed in the past was likely due to the provision of lubricant and inclusion of instructions on how to use the product.
Lubricant reduces friction, which in turn causes condom failure from slippage and breakage.
Another reason could be that participants were asked to keep mobile phone-based daily diaries, whereas past trials had asked volunteers to recall failure events up to several months later.
Monica Gandhi, an infectious disease doctor and medical director of an HIV clinic in San Francisco, welcomed the finding.
"The important thing about condoms is they don't just prevent HIV, but they prevent gonorrhea, chlamydia and syphilis," she told AFP, adding it was surprising that such an authorization had taken so long to achieve.
In its statement, the FDA said the green light could pave the way for more makers to apply for similar authorization if they show equivalent results.
G.AbuGhazaleh--SF-PST